Showing 4911-4920 of 6036 results for "".
- Adverum Biotechnologies Reports a Adverse Reaction of Hypotony in the INFINITY Trial Evaluating ADVM-022 in Patients With DMEhttps://modernod.com/news/adverum-biotechnologies-reports-a-adverse-reaction-of-hypotony-in-the-infinity-trial-evaluating-advm-022-in-patients-with-dme/2479135/Adverum Biotechnologies announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurr
- Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/aerie-pharmaceuticals-announces-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479128/Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases, announced it will participate and have poster
- Novaliq Announces More Than Half of Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2https://modernod.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/Novaliq announced today that the second Phase 3 clinical trial evaluating CyclASol to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the second half of 2021. The Phase 3 program for CyclASol
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2021-arvo-annual-meeting/2479123/Allegro Ophthalmics announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held virtually May 1-7, 2021. “It’s e
- SIFI Initiates Patient Enrollment in Phase 2 Trial Evaluating Pro-Ocular in Dry Eye Diseasehttps://modernod.com/news/sifi-initiates-patient-enrollment-in-phase-2-trial-evaluating-pro-ocular-in-dry-eye-disease/2479120/SIFI announced the enrollment of the first patients in the ProGIFT trial, which aims to evaluate the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with dry eye disease (DED). P<
- Foundation Fighting Blindness Appoints Claire M. Gelfman, PhD, as Chief Scientific Officerhttps://modernod.com/news/foundation-fighting-blindness-appoints-claire-m-gelfman-phd-as-chief-scientific-officer/2479118/Foundation Fighting Blindness announced that it has appointed Claire M. Gelfman, PhD, as chief scientific officer. In her new role, Dr. Gelfman will be responsible for leading the overarching scientific strategy for the organization with a focus on research initiati
- Glaukos Announces Global Licensing Agreement Amendment with Intratus to Include the Treatment of Presbyopiahttps://modernod.com/news/glaukos-announces-global-licensing-agreement-amendment-with-intratus-to-include-the-treatment-of-presbyopia/2479115/Glaukos announced that it has entered into an amended licensing agreement with Intratus under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, noninvasive drug delivery platform (the Eyelid Drug Delivery Platform
- Oertli Launches New Silicone Application Adapterhttps://modernod.com/news/oertli-launches-new-silicone-application-adapter/2479114/Oertli announced it has released a new silicone application that is designed to allow for more user-friendly and efficient surgical preparation. The Oertli silicone application sets deliver fast injection and extraction of silicone oil, according to a company news release. The universal vi
- CHMP Recommends EU Approval of Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/chmp-recommends-eu-approval-of-enspryng-satralizumab-for-neuromyelitis-optica-spectrum-disorder-nmosd/2479111/Chugai Pharmaceutical announced that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody
- US Patents for Nicox’s Vyzulta (Latanoprostene Bunod) Eligible for Patent Term Extensionhttps://modernod.com/news/us-patents-for-nicoxs-vyzulta-latanoprostene-bunod-eligible-for-patent-term-extension/2479103/Nicox SA announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potential